Fluoxetine: activating and sedating effects at multiple fixed doses
- PMID: 1479050
Fluoxetine: activating and sedating effects at multiple fixed doses
Abstract
Serotonin uptake inhibitors are generally considered activating antidepressants. To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746). The adverse events nervousness, anxiety, agitation, and insomnia were considered indicative of activation; somnolence and asthenia were considered indicative of sedation. Activation and sedation were both statistically significant (p less than or equal to 0.05) treatment-emergent phenomena, but dose-effect relationships differed. Activation rates were relatively stable between 5 and 40 mg/day, and then increased at 60 mg/day. Sedation rates increased linearly to 40 mg/day and then were comparable at 40 and 60 mg/day. Discontinuations for either phenomenon were uncommon. The temporal patterns of first occurrences and persistence of activation and sedation differed. First occurrences of activation peaked early and declined over time with all doses. First occurrences of sedation also peaked early with all doses, but there may have been greater variability in first occurrences of sedation over time with lower doses. Persistent occurrences of sedation may decline less over time than persistent occurrences of activation.
Similar articles
-
Fluoxetine: activating and sedating effects.Int Clin Psychopharmacol. 1993 Winter;8(4):271-5. Int Clin Psychopharmacol. 1993. PMID: 8277147 Review.
-
Fluoxetine versus trazodone: efficacy and activating-sedating effects.J Clin Psychiatry. 1991 Jul;52(7):294-9. J Clin Psychiatry. 1991. PMID: 2071559 Clinical Trial.
-
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.J Clin Psychopharmacol. 1991 Jun;11(3):166-74. J Clin Psychopharmacol. 1991. PMID: 2066455 Clinical Trial.
-
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.J Clin Psychiatry. 1994 Oct;55 Suppl:69-76; discussion 77-8. J Clin Psychiatry. 1994. PMID: 7961535 Clinical Trial.
-
Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.Depress Anxiety. 1996-1997;4(6):294-311. doi: 10.1002/(SICI)1520-6394(1996)4:6<294::AID-DA6>3.0.CO;2-C. Depress Anxiety. 1996. PMID: 9166658 Review.
Cited by
-
Advance taper of antidepressants prior to multiple sleep latency testing increases the number of sleep-onset rapid eye movement periods and reduces mean sleep latency.J Clin Sleep Med. 2020 Nov 15;16(11):1921-1927. doi: 10.5664/jcsm.8738. J Clin Sleep Med. 2020. PMID: 32780009 Free PMC article.
-
Behavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidance.Drug Saf. 1998 Mar;18(3):189-208. doi: 10.2165/00002018-199818030-00004. Drug Saf. 1998. PMID: 9530538 Review.
-
Comparative tolerability profiles of the newer versus older antidepressants.Drug Saf. 1994 Jan;10(1):18-46. doi: 10.2165/00002018-199410010-00003. Drug Saf. 1994. PMID: 8136085 Review.
-
Use of Selective Serotonin Reuptake Inhibitors and Sleep Quality: A Population-Based Study.J Clin Sleep Med. 2016 Jul 15;12(7):989-95. doi: 10.5664/jcsm.5932. J Clin Sleep Med. 2016. PMID: 27092698 Free PMC article.
-
A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy.Mayo Clin Proc. 2010 Jun;85(6):538-50. doi: 10.4065/mcp.2009.0565. Epub 2010 Apr 29. Mayo Clin Proc. 2010. PMID: 20431115 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources